PlainPharmaWatch

CMS Open Payments · Tool

Hoffmann-La Roche Limited vs Tyber Medical, LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Tyber Medical, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,309, versus 1,042 for the other company. Its single largest recorded recipient represents 21.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Hoffmann-La Roche Limited
HHI 1,042 · top recipient 20.8%
Ranked #1,013 of 1,838 companies by HHI
Tyber Medical, LLC
HHI 1,309 · top recipient 21.3%
Ranked #917 of 1,838 companies by HHI

Payment Overview

Total Payments
$9.1M
% of Industry
0.1%
Transactions
1,311
Avg per Transaction
$7.0K
Recipients
60
Avg per Recipient
$152.1K
Payment Types
4
Top Payment Type
Consulting Fee
Company B

Tyber Medical, LLC

Total Payments
$9.1M
% of Industry
0.1%
Transactions
45
Avg per Transaction
$201.8K
Recipients
27
Avg per Recipient
$336.3K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Hoffmann-La Roche Limited vs Tyber Medical, LLC - total reported payments in CMS Open Payments PY2024

Hoffmann-La Roche Limited$9.1MTyber Medical, LLC$9.1M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Hoffmann-La Roche Limited

Consulting Fee $180.8K

97.4%

Travel and Lodging $3.9K

2.1%

Compensation for Services Other Than Consulting $527.25

0.3%

Food and Beverage $339.86

0.2%

Tyber Medical, LLC

Consulting Fee $73.0K

76.9%

Space Rental or Facility Fees $14.6K

15.3%

Travel and Lodging $7.3K

7.7%

Food and Beverage $92.16

0.1%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Hoffmann-La Roche Limited

  1. 1

    CARL DANZIG

    $38,583.23 · 5 txns

  2. 2

    PRADEEP YOGANATHAN

    $26,142.34 · 11 txns

  3. 3

    YASHA MODI

    $16,961.79 · 5 txns

  4. 4

    MURTAZA ADAM

    $14,663.97 · 4 txns

  5. 5

    HARIT BHATT

    $14,255.02 · 5 txns

Tyber Medical, LLC

  1. 1

    GORDON D DONALD MD

    $20,250.00 · 2 txns

  2. 2

    BRANDON E EARP MD

    $14,933.08 · 5 txns

  3. 3

    Lehigh Valley

    $14,550.00 · 2 txns

  4. 4

    GAURAV LUTHER MD

    $11,650.00 · 3 txns

  5. 5

    ERIC HOFMEISTER MD

    $8,342.81 · 2 txns

Summary Comparison

Metric Hoffmann-La Roche Limited Tyber Medical, LLC
Total Payments $9.1M $9.1M
% of Industry Total 0.1% 0.1%
Transaction Count 1,311 45
Avg per Transaction $7.0K $201.8K
Recipient Count 60 27
Avg per Recipient $152.1K $336.3K
Payment Type Count 4 4
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.